Free tool
FAERS Monitor: Pivya
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216483 or its brand name (Pivya, Pivmecillinam Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
188
Serious
184
98% of reports
Hospitalization
84
Death reported
19
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malaise20
- confusional state19
- urinary incontinence13
- decreased appetite12
- drug interaction12
- diarrhoea11
- headache11
- rash11
- acute kidney injury10
- hyponatraemia9
- balance disorder8
- decreased interest8
- hypersomnia8
- lip swelling8
- muscular weakness8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 8 |
| 2014 | 1 |
| 2015 | 7 |
| 2016 | 39 |
| 2017 | 6 |
| 2018 | 17 |
| 2019 | 40 |
| 2020 | 21 |
| 2021 | 39 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,971 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| decreased interestSignal | 8 | 152.0 | 77.1 | 1,053 |
| urinary incontinenceSignal | 13 | 49.1 | 29.1 | 566 |
| hypersomniaSignal | 8 | 31.2 | 15.9 | 205 |
| lip swellingSignal | 8 | 26.9 | 13.6 | 175 |
| hyponatraemiaSignal | 9 | 17.9 | 9.5 | 127 |
| confusional stateSignal | 19 | 13.2 | 8.6 | 203 |
| balance disorderSignal | 8 | 10.4 | 5.3 | 59 |
| drug interactionSignal | 12 | 8.5 | 4.9 | 72 |
| muscular weaknessSignal | 8 | 7.9 | 4.0 | 42 |
| acute kidney injurySignal | 10 | 7.3 | 4.0 | 49 |
| decreased appetiteSignal | 12 | 5.8 | 3.3 | 43 |
| malaiseSignal | 20 | 5.1 | 3.4 | 63 |
| rashSignal | 11 | 2.8 | 1.6 | 11 |
| headache | 11 | 2.0 | 1.1 | 4 |
| diarrhoea | 11 | 1.9 | 1.1 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.